Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
GEN reports development of lipid nanoparticles designed to deliver nucleic-acid cargo to lung and eye tissues. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →City of Hope and Cellares agreed to assess Cell Shuttle and Cell Q for solid-tumour CAR T manufacturing and quality control. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →EirGenix gained access to Transcenta's HiCB technologies, which include continuous perfusion and hybrid continuous purification. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →SMRTS is a “smart” mRNA system that switches therapeutic genes on or off depending on cell type, enabling targeted cancer treatments while expanding the mRNA toolbox for precision medicine applications. The post Engineered mRNA System Delivers SMRTS for Cell-Selective Gene Expression appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The Houston facility expands Avance Biosciences' capacity for functional and potency testing during therapy development. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The companies announced a gene-editing collaboration targeting rare liver diseases, marking Chiesi's entry into gene-editing development. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A two-step microfluidics system created ternary nano-scale lipopolyplexes, using polymer choice to determine the lipopolyplexes’ structure, which affects vector size and distribution. This overcomes barriers to manufacturing and creates nonviral vectors for efficient DNA delivery. The post Microfluidics-Manufactured Lipopolyplexes Offer Size Consistency appeared first on GEN - Genetic Engineering The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The agreement supports larger-scale production of RION's platelet-derived exosome therapeutics using the company's manufacturing platform. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →The collaborators plan to extend Cell Q, an automated platform for in-process and release testing at commercial manufacturing scale. The reported capability is a product or workflow announcement, not independent proof of clinical diagnostic performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By wrapping CRISPR’s tools in spherical DNA-coated nanoparticles, researchers tripled gene-editing success rates, improved precision, and dramatically reduced toxicity compared to current methods.
Source: ScienceDaily
Read more →GEN reports research on a polymer-based alternative to PEG in lipid nanoparticles for mRNA delivery. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
